Top Story

Self-expanding peripheral stent system approved by FDA

February 1, 2015

The FDA recently approved a self-expanding peripheral stent system for use in the common iliac, external iliac, superficial femoral and subclavian arteries, according to a press release.

The Protégé GPS Self-Expanding Peripheral Stent System (ev3, Inc.) consists of a stent and delivery system. The nitinol stent comes on a 6F over-the-wire delivery system, and has narrowed edges to avoid irritation or damage to the luminal diameter. The stent has tantalum radiopaque GPS markers on both ends for better visibility and more accurate insertion. The system also features a catheter with zones of varying flexibility and a soft, flexible tip designed for catheter advancement and placement, according to information from the company. Once in place, the stent permanently holds open a narrowed iliac artery and improves blood flow to the pelvis and legs.

William Maisel FDA News

FDA reevaluates safety of automated external defibrillators

January 31, 2015
The FDA recently announced it plans to strengthen its review of automated external defibrillators to help improve the quality and reliability of the devices.According to…

4 things you should know about women’s heart health

January 30, 2015
MI occurs in a woman in the United States every 90 seconds, according to the CDC. The good news is that data from the American Heart Association and the CDC Heart…
In the Journals

NOBORI 1: Low TLR, no stent thrombosis with biodegradable polymer DES at 5 years

January 30, 2015
Five-year data demonstrate that the Nobori drug-eluting stent with biodegradable polymer was safe and durable in patients with de novo coronary artery lesions.The…
Meeting News Coverage

Blood transfusions during CABG increased risk for pneumonia

January 30, 2015
Patients had a greater risk for developing postoperative pneumonia if they received red blood cell transfusions during or after isolated CABG surgery, according to data…
More News Headlines »
Individualizing T2DM Treatment: Determining Optimal Pathways That Lead to Achieving Target Goals

Individualizing T2DM Treatment: Determining Optimal Pathways That Lead to Achieving Target Goals

This activity is supported by educational grants from Lilly USA, LLC and Novo Nordisk.

The prevalence of type 2 diabetes mellitus has escalated in recent years and targeting treatmentcontinues to be a…
More »
Meeting News Coverage Video
thumbnail for video 3945938325001

Kirk N. Garratt, MD: Prolonged DAPT beneficial in patients with paclitaxel-eluting stents

December 16, 2014
CHICAGO — In this video, Kirk N. Garratt, MD, of the Lennox Hill Hospital, New York, outlines results of a study…
More »
Experts Take: Dialogue on HTG

Experts’ Take: Dialogue on Hypertriglyceridemia

This activity is supported by an independent educational grant from Amarin Pharma Inc.

Lead by genetic studies, recent data describe a causal role of triglycerides (TG) in the formation of atherosclerosis…
More »